Phase II Study of Palonosetron, Aprepitant, Dexamethasone and Olanzapine for the Prevention of Cisplatin-Based Chemotherapy-Induced Nausea and Vomiting in Patients With Thoracic Malignancy

摘要

The 3-drug combination of a 5-HT_3 receptor antagonist, aprepitant, and dexamethasone is recommended for patients receiving HEC. Phase 3 studies investigating this 3-drug combination have reported CINV CR rates of approximately 60% to 70% in the overall phase. Olanzapine inhibits several neurotransmitter pathways that are involved in nausea and vomiting, including those mediated by the serotonergic, dopaminergic, α-1 adrenergic, histaminic, and muscarinic receptors. The combination of olanzapine plus standard antiemetic therapy demonstrated efficacy in preventing CINV in several clinical trials of patients receiving HEC.